Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia.
Gavi-AMC
cold chain
multi-dose
potential saving
vaccine price
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
18 May 2020
18 May 2020
Historique:
received:
15
04
2020
revised:
12
05
2020
accepted:
14
05
2020
entrez:
24
5
2020
pubmed:
24
5
2020
medline:
24
5
2020
Statut:
epublish
Résumé
As one of Gavi, the Vaccine Alliance (previously the Global Alliance for Vaccines and Immunization), graduating countries, Indonesia is still eligible to access Gavi price for PCV13, PCV10 A and B. This study aims to estimate the economic impact of switch from the existing product/presentation of PCV (single-dose of PCV13) to the new product/presentation of PCV (multi-dose of PCV13, PCV10 A and B) since PCV is one of the most expensive vaccines in the Expanded Program on Immunization (EPI) schedule. Assuming that Gavi-Advance Market Commitment (AMC) price for all PCVs can be accessed in 2021, the use of multi-dose PCV13, PCV10 A and PCV10 B with Gavi-AMC price in 2021-2024 were considered as respective scenarios. The result showed that the scenario assuming the use of single-dose of PCV13 with contract price in 2019-2020 that would be switched into multi-dose of PCV10 B with Gavi-AMC price in 2021-2024 resulted in the highest potential saving, compared with other scenarios. Our analysis suggests an economic advantage to switch from single-dose into a multi-dose presentation. Vaccination coverage, vaccine price, vaccine wastage and additional Gavi-AMC vaccine costs were considered to be the most influential parameter affecting the savings in all scenarios. Applying the effectiveness of PCV13 and PCV10 A on reducing the risk for invasive pneumococcal disease (IPD), potential averted incidence of IPD in children under one year of age during 2019-2024 would be 246,164 and 105,587 in both scenarios. Despite the result confirmed that PCV13 may provide an additional benefit, a more comprehensive economic evaluation study is required to investigate further the comparison of cost-effectiveness values among all PCVs in Indonesia.
Identifiants
pubmed: 32443523
pii: vaccines8020233
doi: 10.3390/vaccines8020233
pmc: PMC7349927
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Vaccine. 2014 Jul 16;32(33):4119-23
pubmed: 24907487
BMC Med. 2011 May 12;9:53
pubmed: 21569402
Vaccine. 2015 Nov 17;33(46):6145-8
pubmed: 26469718
Lancet Infect Dis. 2005 Feb;5(2):83-93
pubmed: 15680778
Pharmacoeconomics. 2016 Dec;34(12):1211-1225
pubmed: 27510721
Value Health Reg Issues. 2016 Dec;11:24-34
pubmed: 27986195
Value Health Reg Issues. 2013 Sep - Oct;2(2):259-263
pubmed: 29702874
Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44
pubmed: 24340399
Vaccine. 2018 Apr 5;36(15):1934-1940
pubmed: 29526371
Lancet Infect Dis. 2014 Sep;14(9):839-46
pubmed: 25042756
Int J Infect Dis. 2015 Nov;40:95-101
pubmed: 26434380
BMC Infect Dis. 2016 Apr 14;16:149
pubmed: 27080523
Vaccine. 2017 Sep 12;35(38):5186-5193
pubmed: 28797727
Clin Infect Dis. 2019 May 30;68(12):2135-2143
pubmed: 30357326
Vaccine. 2015 May 28;33(23):2684-9
pubmed: 25887086
PLoS One. 2015 Mar 17;10(3):e0120290
pubmed: 25781031
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
Acta Paediatr. 2018 Mar 30;:
pubmed: 29603797
Lancet Infect Dis. 2018 Sep;18(9):945-946
pubmed: 30152356
Bull World Health Organ. 2011 Dec 1;89(12):913-8
pubmed: 22271949
Vaccine. 2013 Apr 18;31 Suppl 2:B81-96
pubmed: 23598496
PLoS One. 2016 Aug 15;11(8):e0161257
pubmed: 27526117
Lancet Infect Dis. 2018 Aug;18(8):830-831
pubmed: 30001857
Expert Rev Vaccines. 2018 Jun;17(6):513-524
pubmed: 29920121
Vaccine. 2017 May 19;35(22):2882-2891
pubmed: 28449971
PLoS One. 2018 Apr 12;13(4):e0195098
pubmed: 29649269
PLoS One. 2016 Dec 12;11(12):e0166736
pubmed: 27941979
Lancet Respir Med. 2014 Jun;2(6):464-71
pubmed: 24726406
PLoS One. 2019 Feb 19;14(2):e0212295
pubmed: 30779801
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
Vaccine. 2012 Jul 6;30(32):4717-8
pubmed: 22621828
Clin Infect Dis. 2015 Dec 1;61(11):1637-44
pubmed: 26374816
Pediatr Infect Dis J. 2001 Nov;20(11 Suppl):S23-9
pubmed: 11704720
Expert Rev Vaccines. 2020 Nov;19(11):1011-1022
pubmed: 31751159
Hum Vaccin. 2010 Mar 21;6(3):
pubmed: 20009517
Wkly Epidemiol Rec. ;92(48):729-47
pubmed: 29192459
Clin Vaccine Immunol. 2011 Feb;18(2):327-36
pubmed: 21123523
Vaccine. 2016 Apr 19;34(18):2062-5
pubmed: 26920471
Pediatr Infect Dis J. 2016 Jul;35(7):787-93
pubmed: 27088583
PLoS One. 2017 Aug 14;12(8):e0183191
pubmed: 28806737
Expert Rev Vaccines. 2018 Sep;17(9):797-818
pubmed: 30185083
Dtsch Arztebl Int. 2016 Mar 4;113(9):139-46
pubmed: 26987462
Vaccine. 2017 Oct 13;35(43):5776-5785
pubmed: 28911902
Pediatr Infect Dis J. 2016 Apr;35(4):e124-33
pubmed: 26974752
Southeast Asian J Trop Med Public Health. 2016 May;47(3):485-93
pubmed: 27405132
Pneumonia (Nathan). 2017 Mar 25;9:6
pubmed: 28702308
Lancet Respir Med. 2016 May;4(5):399-406
pubmed: 26987984
BMC Public Health. 2018 Jul 11;18(1):864
pubmed: 29996802
Int J Infect Dis. 2020 Mar;92:261-268
pubmed: 32147023
Lancet Infect Dis. 2018 Aug;18(8):831-832
pubmed: 30001856